RxDoctor Payments Data

Jane Curtis, MD

Internal Medicine · Santa Ana, CANPI 1518018217

Payments from drug & device makers

$2,595in general payments, 2019–2025

Across 118 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$856
  • Novo Nordisk$312
  • AbbVie$258
  • Lilly USA, LLC$225
  • Collegium Pharmaceutical, Inc.$218
  • Pfizer$142
  • plus $583 from 17 others

What the payments were for

  • Consulting fees$120%
  • Food & beverage$2,583100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,595 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$116,820
Medicare patients
305
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$76,829
EliquisApixaban77$76,515
RybelsusSemaglutide44$73,653
TrulicityDulaglutide39$68,360
FarxigaDapagliflozin Propanediol31$42,755
MounjaroTirzepatide36$40,507
JardianceEmpagliflozin24$30,583
ProliaDenosumab16$27,326
LinzessLinaclotide26$24,684
BelsomraSuvorexant14$13,328
Budesonide ErBudesonide11$12,988
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,820
Atorvastatin Calcium674$7,277
Estradiol105$5,365
Levothyroxine Sodium422$5,262

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$312$150,48292 claims
Lilly USA, LLCTrulicity, Mounjaro$225$108,86675 claims
PfizerEliquis, Paxlovid$142$77,94592 claims
AstraZenecaFarxiga, Breztri Aerosphere$856$55,57542 claims
AbbVieLinzess, Synthroid$258$29,91176 claims
AmgenProlia$77$27,32616 claims
MerckBelsomra$55$13,32814 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$37$4,90114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →